Drug Trial Radar · NCT03038100
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Last checked: Nov 20, 2026Latest source record: Feb 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,301
Actual
Start
Mar 8, 2017
Primary completion
Feb 8, 2022
Study completion Aug 12, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
- First posted
- Jan 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
Interventions
PaclitaxelDrug
Paclitaxel 175 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of each 21-day cycle
CarboplatinDrug
Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 of each 21-day cycle for a total of 6 cycles
AtezolizumabDrug
Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
BevacizumabDrug
Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
Atezolizumab PlaceboDrug
Placebo matching to atezolizumab on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) PopulationTime frame: From randomization until disease progression or death from any cause (up to approximately 55 months)
- PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive SubpopulationTime frame: From randomization until disease progression or death from any cause (up to approximately 55 months)
- Overall Survival - ITT PopulationTime frame: From randomization up to death from any cause (up to approximately 59 months)
- Overall Survival - PD-L1-Positive SubpopulationTime frame: From randomization up to death from any cause (up to approximately 59 months)
Locations
268 sites in 22 countries. Site status is shown where the registry gives one.
St. Joseph'S Hospital & Medical Center
Phoenix, Arizona
Arizona Oncology Associates, PC - HAL
Scottsdale, Arizona
Arizona Oncology - HOPE Wilmot
Tucson, Arizona
Moores Cancer Center at UC San Diego Health
La Jolla, California
LAC + USC Medical Center
Los Angeles, California
UCLA - School of Medicine
Los Angeles, California
Kaiser Permanente - Oakland
Oakland, California
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange
Orange, California
UC Irvine Medical Center
Orange, California
Stanford University
Palo Alto, California
Kaiser Permanente - Sacramento
Roseville, California
Southern California Kaiser Permanente
San Diego, California
California Pacific Medical Center Research Institute
San Francisco, California
K. Permanente - San Fransisco
San Francisco, California
University of California San Francisco Cancer Center
San Francisco, California
Kaiser Permanente - Santa Clara
Santa Clara, California
Olive View/Ucla Medical Center
Sylmar, California
Kaiser Permanente - Walnut Creek
Walnut Creek, California
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado
Danbury Hospital
Danbury, Connecticut
Eastern Connecticut Hematology and Oncology Associates; (ECHO)
Norwich, Connecticut
Sylvester Comprehensive Cent.
Miami, Florida
Miami Cancer Institute of Baptist Health, Inc.
Miami, Florida
Sarasota Memorial Health Care System; Cancer Research Program
Sarasota, Florida
Women's Cancer Associates
St. Petersburg, Florida
Northside Hospital
Atlanta, Georgia
Northeast Georgia Medical Center; Oncology Research Dept-5C
Gainesville, Georgia
Women's Cancer Center
Honolulu, Hawaii
Rush University Medical Center
Chicago, Illinois
Univ of Chicago
Chicago, Illinois
Sudarshan K. Sharma, MD, Ltd.
Hinsdale, Illinois
Parkview Research Center
Fort Wayne, Indiana
St.Vincent Health System; Gynecologic Oncology
Indianapolis, Indiana
University of Iowa Hospital & Clinic; Division of Hematology/Oncology
Iowa City, Iowa
University of Kentucky; Gynecologic Oncology
Lexington, Kansas
St. Elizabeth Edgewood; Cancer Care Center? for Account St. Elizabeth Edgewood
Edgewood, Kentucky
Woman's Hospital
Baton Rouge, Louisiana
Maine Medical Partners Women's Health; Gyn-Oncology
Scarborough, Maine
Greater Baltimore Medical Center
Baltimore, Maryland
Sinai Hospital of Baltimore
Baltimore, Maryland
Showing 40 of 268 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.